Cytoreductive nephrectomy for metastatic renal cell carcinoma.
The incidence of renal cell carcinoma is increasing, with up to one-third of patients presenting with metastatic disease. Combination therapy is used to prolong survival in patients with metastatic renal cell carcinoma, which carries a poor prognosis. Although two pivotal phase 3 trials have demonstrated the efficacy of immunotherapy after cytoreductive nephrectomy for metastatic disease, for now, targeted therapy has replaced immunotherapy as the preferred systemic treatment in these patients. Two ongoing phase 3 trials are evaluating the role of cytoreductive nephrectomy prior to targeted therapy. Proper patient selection is paramount in achieving successful outcomes.
The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lisly J
LJ
Chery
The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jose A
JA
Karam
The University of Texas MD Anderson Cancer Center, Houston, Texas.
Christopher G
CG
Wood
D002292:Carcinoma, Renal Cell / Q000601:surgery*; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures / Q000379:methods*; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery*; D058990:Molecular Targeted Therapy / Q000379:methods; D020360:Neoadjuvant Therapy / Q000379:methods; D009392:Nephrectomy / Q000379:methods*